IND-Enabling Program Support
Sinclair Research offers full-service IND-enabling toxicology and safety pharmacology services at a single research site. Whether your program is in late-stage discovery or entering clinical trials, Sinclair Research provides the services you need, the data you expect and the customer service you deserve.
The services you expect. The data you need. The customer experience you deserve.
Built on more than 50 years of experience, Sinclair Research provides research services to support biopharmaceutical, animal health and medical device development programs. As one of the largest nonclinical CROs in North America, Sinclair Research’s scientific and technical expertise can provide you with the services you need, the data you expect, and the customer experience you deserve! Contact our team to discuss your upcoming research and meet with our scientific experts to discuss how to reach your next development milestone.
Our Latest News
Sinclair Research Appoints Sandra Love as Director of Safety Pharmacolog
Sinclair Research, a leading provider of nonclinical research services, has named Dr. Sandra Love, PhD as Director of Safety Pharmacology. In this role, Dr. Love will lead Sinclair’s Safety Pharmacology program and consult on the design and development of in vivo pharmacology disease models to support current and prospective customers.
Get A Glimpse of Our Newly Opened Toxicology Lab Expansion!
Sinclair Research recently expanded its GLP nonclinical toxicology facility by adding additional research space dedicated to support nonclinical toxicology research. The new expansion increases our room capacity by more than 25 percent, allowing Sinclair to continue to offer rapid study starts and support increasing demand for outsourced drug development services.
Sinclair Research Announces Successful Validation of GLP Safety Pharmacology Services
Sinclair Research, a leading provider of nonclinical contract research services, today announced the successful GLP validation of its Safety Pharmacology services in partnership with CorDynamics, a premier provider of cardiovascular toxicology and safety pharmacology contract research services.
Our virtual audit solution provides a fully customizable alternative to in-person facility qualifications, audits and tours!
Sinclair Research’s virtual audits offer an innovative way to overcome the obstacles raised by the global pandemic. Virtual audits are built with flexibility in mind, allowing you to customize your audit to meet your individual needs. Our secure virtual platform is designed to quickly and effectively share the information you need to conduct a comprehensive virtual audit or facility tour. From the initial planning meeting to the completion of your virtual audit, Sinclair Research’s team of scientific and quality experts will be at your service, just as they would if you were physically on site.
Our upcoming Events
ACT 42nd Annual Meeting
Sinclair Research is proud to be attending this year’s ACT 42nd Annual Meeting. Visit our booth and let us show you how the scientific experts at Sinclair Research can help accelerate your #nonclinical #development timelines!
Watch our latest on-demand webinar: "505(b)(2) Formulation Considerations for New Topical Drug Products"
Watch our latest on-demand webinar as Tioga Research CEO, Dr. John M. Newsam, and Sinclair Research’s Director of Toxicology and Dermatology, Dr. Jeffrey Klein, PhD, DABT share their insight on how 505(b)(2) topical drug products extend market exclusivity!
Watch our on-demand webinar:“How Do I Get Into Phase 1 Trials with My Compound?”
Watch our on-demand webinar “How Do I Get Into Phase 1 Trials with My Compound?” Presented by Sinclair Research’s Senior Vice President of Research, Dr. Scott E. Boley, PhD, DABT, this live webinar will explore how to get your compound into Phase 1 trials.